What is Haemonetics's payments of debt issuance costs?

Haemonetics (HAE) reported payments of debt issuance costs of $0 in Q1 2026.

What is the long-term trend for Haemonetics's payments of debt issuance costs?

Over 2 years (2023 to 2026), Haemonetics's payments of debt issuance costs has grown at a -100.0% compound annual growth rate (CAGR), from $1.12M to $0.

Haemonetics HAE Payments Of Debt Issuance Costs

Payments Of Debt Issuance Costs at other companies

LeMaitre VascularLMAT

——

RepligenRGEN

——

RevvityRVTY

——

Other financials

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

See full

Market cap$3.31B-18.0%

Profitability

See full

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's payments of debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Haemonetics's payments of debt issuance costs?: Haemonetics (HAE) reported payments of debt issuance costs of $0 in Q1 2026.
What is the long-term trend for Haemonetics's payments of debt issuance costs?: Over 2 years (2023 to 2026), Haemonetics's payments of debt issuance costs has grown at a -100.0% compound annual growth rate (CAGR), from $1.12M to $0.